Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition | New
England Journal of Medicine Skip to main content The New England Journal of Medicine …

The concept of engineering robust protein scaffolds for novel binding functions emerged 20
years ago, one decade after the advent of recombinant antibody technology. Early examples …

The complement cascade is an ancient immune‐surveillance system that not only provides
protection from pathogen invasion but has also evolved to participate in physiological …

Blocking the terminal complement pathway with the C5 inhibitor eculizumab has
revolutionized the clinical management of several complement-mediated diseases and has …

Complement is one of the most ancient defense systems. It gets strongly activated
immediately after acute injuries like trauma, burn, or sepsis and helps to initiate …

Eculizumab inhibits the terminal, lytic pathway of complement by blocking the activation of
the complement protein C5 and shows remarkable clinical benefits in certain complement …

Saliva of ticks is arguably the most complex saliva of any animal. This is particularly the case
for ixodid species that feed for many days firmly attached to the same skin site of their …

Introduction The complement system is a key component of the innate immune system, and
its aberrant activation underlies the pathophysiology of various diseases. Zilucoplan is a …

Age-related macular degeneration (AMD) remains a major cause of legal blindness, and
treatment for the geographic atrophy form of AMD is a significant unmet need. Dysregulation …

Complement activation in the diseases paroxysmal nocturnal hemoglobinuria (PNH) and
atypical hemolytic uremic syndrome (aHUS) results in cytolysis and fatal thrombotic events …